Current Studies
Rochester Victory Alliance is enrolling for HVTN-sponsored HIV studies, and is taking part in HVTN’s COVID-19 research to help find effective treatments, as well.
Below is a listing of our current and upcoming studies, along with study enrollment criteria.
Current HIV Vaccine Studies
HVTN 206 — bnAb Combo Qualifier
enrolling
(ClinicalTrials.gov link: NCT06812494)
Broadly neutralizing antibodies (bnAbs, pronounced bee‐nabs) are antibodies that can fight back against many strains of HIV all at the same time.
Researchers believe that giving combinations of bnAbs increases the chances that more HIV is blocked. This study focuses on three bnABs that have been copied and manufactured in a lab.
These antibodies have been studied in several previous trials. This is a Phase 2 study which involves infusing the antibodies through an IV. Participants will receive two separate infusions of the three study antibodies.
Study vaccines used in this study are not made from live or killed HIV. These study vaccines cannot cause HIV infection or AIDS.
This study will enroll up to 200 participants, with about 10 clinic visits over about 12 months.
Eligibility criteria:
- HIV-negative;
- Between 18–65 years old;
- BMI < 40; and
- In good general health.
Contact us
HVTN 321 - V3-glycan
enrolling
(ClinicalTrials.gov link: NCT06919016)
Two mRNA vaccines are being studied in this trial. This study will enroll 45 participants, with about 12 clinic visits and four non-clinic visits over about 16 months. Each participant will get both vaccines.
Study vaccines used in this study are not made from live or killed HIV. These study vaccines cannot cause HIV infection or AIDS.
Eligibility criteria:
- HIV-negative;
- Between 18–55 years old;
- BMI < 40; and
- In good general health.
Contact us
HVTN 319 — UVax Bio
screening on hold
(ClinicalTrials.gov link: NCT06905275)
This is a Phase 1 study of two experimental vaccines with an adjuvant (a compound added to heighten immune response). Both study vaccine includes a man-made protein that looks like a protein found on the outside of HIV.
Study vaccines used in this study are not made from live or killed HIV. These study vaccines cannot cause HIV infection or AIDS.
This study will enroll 25 participants, with about 12 clinic visits over about 12 months.
Eligibility criteria:
- HIV-negative;
- Between 18–55 years old;
- BMI < 40; and
- In good general health.
Contact us
HVTN 313– Fusion Peptide Vaccine Study
enrollment full
ClinicalTrials.gov link: NCT06332339
This study is investigating three vaccines. Two of the vaccines are protein vaccines made to resemble a piece of protein on the surface of HIV. The third vaccine is an intranasal vaccine, made using an adenovirus; adenoviruses e viruses that cause illnesses like the common cold.
Because adenoviruses can be contagious, household contacts of participants are also invited to join the study for follow-up. Household contacts must be over the age of 18 and not be immunocompromised.
Study vaccines used in this study are not made from live or killed HIV. These study vaccines cannot cause HIV infection or AIDS.
Eligibility criteria:
- HIV-negative;
- Between 18–55 years old;
- BMI < 40; and
- In good general health.
Contact us